DE69900847T2 - Map kinase-inhibitoren zur behandlung von durch tnf-alpha induzierte lipolyse- verursachte krankheiten - Google Patents

Map kinase-inhibitoren zur behandlung von durch tnf-alpha induzierte lipolyse- verursachte krankheiten

Info

Publication number
DE69900847T2
DE69900847T2 DE69900847T DE69900847T DE69900847T2 DE 69900847 T2 DE69900847 T2 DE 69900847T2 DE 69900847 T DE69900847 T DE 69900847T DE 69900847 T DE69900847 T DE 69900847T DE 69900847 T2 DE69900847 T2 DE 69900847T2
Authority
DE
Germany
Prior art keywords
signal transduction
transduction pathway
tnf
alpha
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69900847T
Other languages
English (en)
Other versions
DE69900847D1 (de
Inventor
S Greenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts University filed Critical Tufts University
Application granted granted Critical
Publication of DE69900847D1 publication Critical patent/DE69900847D1/de
Publication of DE69900847T2 publication Critical patent/DE69900847T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
DE69900847T 1998-04-17 1999-04-16 Map kinase-inhibitoren zur behandlung von durch tnf-alpha induzierte lipolyse- verursachte krankheiten Expired - Fee Related DE69900847T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8215298P 1998-04-17 1998-04-17
US8274198P 1998-04-23 1998-04-23
PCT/US1999/008364 WO1999053927A1 (en) 1998-04-17 1999-04-16 Methods for treating and preventing insulin resistance and related disorders

Publications (2)

Publication Number Publication Date
DE69900847D1 DE69900847D1 (de) 2002-03-14
DE69900847T2 true DE69900847T2 (de) 2002-09-12

Family

ID=26767120

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69900847T Expired - Fee Related DE69900847T2 (de) 1998-04-17 1999-04-16 Map kinase-inhibitoren zur behandlung von durch tnf-alpha induzierte lipolyse- verursachte krankheiten

Country Status (4)

Country Link
EP (1) EP1071429B1 (de)
AT (1) ATE212552T1 (de)
DE (1) DE69900847T2 (de)
WO (1) WO1999053927A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119114B1 (en) 1999-08-19 2006-10-10 Signal Pharmaceuticals, Llc Pyrazoloanthrone and derivatives thereof as JNK inhibitors and compositions and methods related thereto
US20040072888A1 (en) 1999-08-19 2004-04-15 Bennett Brydon L. Methods for treating inflammatory conditions or inhibiting JNK
SE0000718D0 (sv) * 2000-03-03 2000-03-03 Pharmacia & Upjohn Ab New use
HUP0301146A3 (en) * 2000-04-28 2004-08-30 Sankyo Co 2-chlor-5-nitrophenyl carboxamide derivatives, pharmaceutical compositions containing them and their use
US7211594B2 (en) 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US7429599B2 (en) 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
US6987184B2 (en) 2001-02-15 2006-01-17 Signal Pharmaceuticals, Llc Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related
EP1390052A4 (de) * 2001-04-24 2008-10-08 Harvard College Hemmung von jun kinase
AR035971A1 (es) 2001-05-16 2004-07-28 Cephalon Inc Metodos para el tratamiento y la prevencion del dolor
WO2003075917A1 (en) 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Combination therapy for treating, preventing or managing proliferative disorders and cancers
NZ537208A (en) * 2002-06-27 2009-02-28 Adipogen Pharmaceuticals Pty Ltd Differentiation modulating agents and uses therefor
JP4705782B2 (ja) * 2002-10-23 2011-06-22 スキャンポ・アーゲー 肥満の処置のためのプロスタグランジン化合物
EP2772140B1 (de) 2003-11-25 2017-04-05 Virginia Tech Intellectual Properties, Inc. Zusammensetzung zur Verringerung der MAP-Kinaseaktivität in Tieren
BRPI0817527A2 (pt) 2007-10-01 2017-05-02 Isis Pharmaceuticals Inc modulação antissenso da expressão do receptor de fator de crescimento de fibroblasto humano 4
EP2721156B1 (de) 2011-06-16 2016-12-21 Ionis Pharmaceuticals, Inc. Antisense-modulierung der expression des fibroblastenwachstumsfaktor-rezeptors 4

Also Published As

Publication number Publication date
EP1071429B1 (de) 2002-01-30
WO1999053927A1 (en) 1999-10-28
ATE212552T1 (de) 2002-02-15
EP1071429A1 (de) 2001-01-31
DE69900847D1 (de) 2002-03-14

Similar Documents

Publication Publication Date Title
DE69900847D1 (de) Map kinase-inhibitoren zur behandlung von durch tnf-alpha induzierte lipolyse- verursachte krankheiten
ATE323482T1 (de) Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten
ATE409466T1 (de) Verfahren und zusammensetzung zur behandlung von diabetes, hypertonie, chronischer herzinsuffizienz und mit flüssigkeitsretention einhergehenden zuständen
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE207349T1 (de) Thip zur behandlung von schlafstörungen
DE69924641D1 (de) Behandlung von asthma anhand von mek-inhibitoren
NO903944L (no) Fremgangsmaate for fremstilling av nye peptidase og isomerase-inhibitorer.
DE60215787D1 (de) Behandlung von typ ii diabetes mit dipeptidyl-peptidase-iv-hemmern
ATE451930T1 (de) Verwendung von il-18-hemmern zur behandlung oder prävention von sepsis
ATE491444T1 (de) Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor- antagonisten und eines nsaid und diese enthaltende zusammensetzung
DE60113815D1 (de) Behandlung cytokin-vermittelter krankheiten mit tec familie protein tyrosin kinase inhibitoren
ATE298566T1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
ATE395083T1 (de) Verfahren zur behandlung von multipler sklerose durch hemmung der il-17-aktivität
DE60117607D1 (de) Verfahren zur Behandlung von mit p38-Kinase assoziierten Leiden und Pyrrolotriazin-Verbindungen als Kinaseinhibitoren.
DE69833971D1 (de) Verfahren zur behandlung von alzheimerschen krankheit
HUP0200026A2 (hu) Eljárás terhelés által indukált asztma kezelésére
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
ATE356995T1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
ATE541565T1 (de) Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
ATE486612T1 (de) Verfahren zur behandlung von diabetes typ 2
DE60231896D1 (de) Zusammensetzungen und verfahren zur erhöhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus
DE69733557D1 (de) Endothelin-antagonisten zur behandlung von herzversagen
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
DE602004022423D1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee